Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 22;12:73–83. doi: 10.2147/COPD.S122013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Simeone et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Sample selection for Objective 2 (to describe the demographic and clinical characteristics, and health care resource use of patients with COPD prior to initiation of a triple therapy maintenance regimen [LAMA/LABA/ICS]).

Notes: IMS PharMetrics Plus database from January 1, 2009 to December 31, 2013. *Defined as ICD-9-CM code for 491.xx (chronic bronchitis), 492.xx (emphysema), or 496.xx (COPD, unspecified) in primary or secondary position.

Abbreviations: ICD-9-CM, International Classification of Diseases – Ninth Revision – Clinical Modification; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic receptor antagonist.